Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the best dose of ACY-1215 in combination with
lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple
myeloma. Once determined, the purpose of this study will be to determine the efficacy of
ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed
multiple myeloma who have had 1-3 prior therapies and who are not lenalidomide-refractory.